Case report of novel CACNA1A gene mutation causing episodic ataxia type 2

David Alan Isaacs, Michael J Bradshaw, Kelly Brown and Peter Hedera

Abstract

**Background:** Episodic ataxia type 2 (OMIM 108500) is an autosomal dominant channelopathy characterized by paroxysms of ataxia, vertigo, nausea, and other neurologic symptoms. More than 50 mutations of the CACNA1A gene have been discovered in families with episodic ataxia type 2, although 30%–50% of all patients with typical episodic ataxia type 2 phenotype have no detectable mutation of the CACNA1A gene.

**Case:** A 46-year-old Caucasian man, with a long history of bouts of imbalance, vertigo, and nausea, presented to our hospital with 2 weeks of ataxia and headache. Subsequent evaluation revealed a novel mutation in the CACNA1A gene: c.1364 G > A Arg455Gln. Acetazolamide was initiated with symptomatic improvement.

**Conclusion:** This case report expands the list of known CACNA1A mutations associated with episodic ataxia type 2.

Keywords

neurology, episodic ataxia, CACNA1A

Date received: 6 January 2017; accepted: 29 March 2017

Introduction

Episodic ataxia type 2 (EA2) is an autosomal dominant channelopathy characterized by paroxysms of ataxia, vertigo, nausea, and occasionally diplopia, tinnitus, dystonia, hemiplegia, and migraine.\(^1\)\(^2\) The typical onset is in childhood and adolescence.\(^1\) Attacks persist for minutes (usually more than 10 min)\(^3\) or days and can be precipitated by stress, exertion, caffeine, and alcohol.\(^1\)

Of the seven subtypes of episodic ataxia so far described, EA2 is the most prevalent.\(^4\) EA2 is allelic with spinocerebellar ataxia 6 (SCA6) and familial hemiplegic migraine, all involving mutations of the CACNA1A gene on chromosome 19p13, which encodes Cav2.1, the pore-forming alpha-1 subunit of the P/Q-type voltage-gated calcium channel.\(^1\)\(^5\) More than 50 mutations have been discovered in families with EA2, the majority involving a truncation mutation, although missense mutations have also been reported.\(^5\)\(^-\)\(^7\) We report a patient with a novel missense mutation in CACNA1A presenting with a phenotype consistent with episodic ataxia.

Case study

A 46-year-old Caucasian man with no medical history developed worsening headache, diplopia, and difficulty with ambulation over 2 weeks. The headache was holoccephalic but with left frontal predominance and was associated with mild photophobia but no phonophobia or nausea.

The patient was evaluated by an ophthalmologist, who detected no intra-ocular pathology, and a neurologist, who noted “extraocular movement abnormalities,” as well as significant truncal and appendicular ataxia. Brain magnetic resonance imaging (MRI) was reportedly normal, and he was given a 3-day course of prednisone. While on prednisone, the headache, horizontal diplopia, and incoordination all improved; however, within days of completion, his neurologic syndrome reemerged with the addition of tinnitus and bradycardia. No infectious symptoms occurred during or prior to presentation. His medications were fish oil and omeprazole.

Two weeks after symptom-onset, the patient presented to our institution. Examination demonstrated bilaterally impaired upgaze with intact downgaze, limitation of left eye adduction, mild ataxic dysarthria, and significant axial and appendicular ataxia involving all limbs. Unremarkable laboratory testing
The mutation was likely deleterious. We analyzed the analysis conducted with SIFT software also indicated that abnormalities.

ular movements had normalized, with no pursuit or saccade average. At his 9-month follow-up appointment, his extraocular movements had normalized, with no pursuit or saccade average. Of critical significance, at that time he recalled that, since his teenage years, he had experienced episodes of rapid-onset ataxia with associated vertigo and nausea. The episodes would last a few days to a week and occurred 2–3 times per year. No maternal family members manifested similar symptoms; his paternal family history was unknown. The patient’s two children have no neurologic symptoms.

Given this additional history, analysis of the following genes was ordered from Athena diagnostics: CACNA1A, CACNB4, KCNA1, and SLC1A3. A novel heterozygous mutation in the CACNA1A gene was identified: c.1364 G > A Arg455Gln. The patient’s genetic mutation was confirmed at our laboratory with bidirectional Sanger sequencing (Figure 1). This variant was previously identified in the 1000 Genomes Project Phase 3 as rs561858384, with a very low frequency (minor allele frequency (MAF) < 0.01). Such variants identified in population-wide genetic studies often represent incidental findings, with no clear pathological significance. However, in silico analysis using PolyPhen-2 software showed that this missense mutation is probably damaging, with a score of 1.00 (highest possible score); analysis conducted with SIFT software also indicated that the mutation was likely deleterious. We analyzed the patient’s mother’s DNA; she was not found to have the mutation. His father was unavailable for testing.

Acetazolamide 250 mg twice daily was initiated, with marked reduction in the severity of ataxic episodes, although they still occurred 2–3 times per year and lasted 1 day on average. At his 9-month follow-up appointment, his extraocular movements had normalized, with no pursuit or saccade abnormalities.

**Discussion**

As mentioned in the “Introduction” section, more than 50 mutations in CACNA1A have been discovered in families with EA2, with pathologic effects primarily attributed to haploinsufficiency. The loss-of-function results in diminished calcium-channel density and reduced calcium currents, causing excessive release of neurotransmitter, predominant symptoms being mainly attributable to overabundant GABA (gamma-aminobutyric acid) in cerebellar Purkinje and granule cells, and acetylcholine at the neuromuscular junction. Approximately 30%–50% of all patients with typical EA2 phenotype have no detectable mutation of the CACNA1A gene, indicating genotypic heterogeneity. Intra- and interfamilial clinical heterogeneity highlight the lack of genotype-phenotype correlation. In the case presented above, our data support that the detected mutation c.1364 G > A Arg455Gln is a disease-causing mutation. The most likely explanation for its prior detection as a rare variant of unknown significance is reduced penetration of the mutation.

This case report demonstrates several typical, as well as a few atypical, features of EA2 in a patient with a novel CACNA1A mutation. While most attacks of EA2 persist only for minutes or days, longer duration episodes, such as our patient experienced on presentation, have previously been reported in genetically confirmed cases (see Patient 7 in Mantuano et al.). It is notable that our patient’s prior attacks, though less severe, lasted several days to 1 week; he consistently experienced paroxysms of greater duration than typical for EA2. Attacks can be associated with headache, as in our patient, and at least 50% of patients with EA2 suffer from migraines.

Interictal nystagmus and ataxia are often but not universally present in EA2. Additional neuro-ophthalmologic signs include impaired visual tracking, optokinetic nystagmus, and suppression of the vestibulo-ocular reflex, as well as saccadic dysmetria and reduced saccade velocity. Our patient demonstrated impaired upgaze at his follow-up visits, in the absence of ataxia or other neurologic symptoms; interestingly, his eye movements were normal at his 9-month follow-up appointment, his extraocular movements had normalized, with no pursuit or saccade abnormalities.

**Figure 1.** Sanger sequence of control and patient DNA: upper panel shows a wild-type (normal) sequence and lower panel shows a heterozygous c.1364 G > A mutation (arrow).
follow-up, though interictal symptoms often do not respond to acetazolamide. Many patients with EA2 develop progressive interictal ataxia,\textsuperscript{3,12} emphasizing the phenotypic overlap with its allelic disorder, SCA6.

Both acetazolamide and 4-aminopyridine reduce the frequency of attacks,\textsuperscript{1} and our patient has noted significant improvement on low-dose acetazolamide. It is difficult to interpret our patient’s symptomatic improvement following initiation of steroids and decline upon steroid withdrawal. We were unable to find any reports in the literature describing steroid administration as a treatment for EA2.

**Acknowledgements**

The authors would like to thank the patient and his family for consenting to publication.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Informed consent**

Written informed consent was obtained from the patient for his anonymized information to be published in this article.

**References**

1. Spacey S. *Episodic ataxia type 2* (ed RA Pagon, MP Adam, HH Ardinger, et al.) Seattle, WA: GeneReviews\textsuperscript{®}, 1993.
2. Nachbauer W, Nocker M, Karner E, et al. Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature. *J Neurol* 2014; 261(5): 983–991.
3. Jen J, Kim GW and Baloh RW. Clinical spectrum of episodic ataxia type 2. *Neurology* 2004; 62(1): 17–22.
4. Wan J, Mamsa H, Johnston JL, et al. Large genomic deletions in CACNA1A cause episodic ataxia type 2. *Front Neurol* 2011; 2: 51.
5. Jen JC, Graves TD, Hess EJ, et al. Primary episodic ataxias: diagnosis, pathogenesis and treatment. *Brain* 2007; 130(Pt 10): 2484–2493.
6. Strupp M, Zwergal A and Brandt T. Episodic ataxia type 2. *Neurotherapeutics* 2007; 4(2): 267–273.
7. Mantuano E, Romano S, Veneziano L, et al. Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. *J Neurol Sci* 2010; 291(1–2): 30–36.
8. ENSEMBL database, http://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;g=ENSG00000141837;r=19:13317256-13734804;r=ENST00000360228;r=rs561858384;vdb=variation;vf=94453989 (accessed March 2017).
9. PolyPhen2, http://genetics.bwh.harvard.edu/pph2/ (accessed March 2017).
10. SIFT, http://sift.jcvi.org/ (accessed March 2017).
11. Baloh RW, Yue Q, Furman JM, et al. Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p. *Ann Neurol* 1997; 41(1): 8–16.
12. Kipfer S and Strupp M. The clinical spectrum of autosomal-dominant episodic ataxias. *Mov Disord Clin Pract* 2014; 1(4): 285–290.